The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population
Abstract
Data are limited on the epidemiological implications of the recent change in terminology from nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction‐associated fatty liver disease (MAFLD). We therefore performed a cross‐sectional study of adults recruited in the 2017‐2018 National Health and Nutrition Examination Survey, a representative sample of the general US population. The prevalence of NAFLD and MAFLD based on controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) obtained through vibration‐controlled transient elastography (VCTE) were 37.1% (95% CI 34.0‐40.4) and 39.1% (95% CI 36.3‐42.1), respectively, with higher rates among Hispanic individuals. Agreement between the two definitions was high (Cohen's κ 0.92). Patients with NAFLD and MAFLD also showed similar risk of advanced liver fibrosis (7.5% and 7.4% respectively). Our results suggest that the recent change in diagnostic criteria did not affect the prevalence of the condition in the general United States population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Sterling, R. K., Lissen, E., Clumeck, N., Sola, R., Correa, M. C., Montaner, J., S. Sulkowski, M., Torriani, F. J., Dieterich, D. T., Thomas, D. L., et al. (2006) · Hepatology · doi:10.1002/hep.21178 · Cited by 5,021
MAFLD identifies patients with significant hepatic fibrosis better than NAFLD
Yamamura, S., Eslam, M., Kawaguchi, T., Tsutsumi, T., Nakano, D., Yoshinaga, S., Takahashi, H., Anzai, K., George, J., & Torimura, T. (2020) · Liver International · doi:10.1111/liv.14675 · Cited by 401
Cited by
Chan, K. E., Koh, T. J. L., Tang, A. S. P., Quek, J., Yong, J. N., Tay, P., Tan, D. J. H., Lim, W. H., Lin, S. Y., Huang, D., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac321 · Cited by 315
Liver fibrosis, NT-ProBNP and mortality in patients with MASLD: A population-based cohort study
Ciardullo, S., Cannistraci, R., Muraca, E., Zerbini, F., & Perseghin, G. (2024) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.11.011 · Cited by 20
Self-citationFrom NAFLD to MAFLD: Aligning Translational In Vitro Research to Clinical Insights
Gatzios, A., Rombaut, M., Buyl, K., De Kock, J., Rodrigues, R. M., Rogiers, V., Vanhaecke, T., & Boeckmans, J. (2022) · Biomedicines · doi:10.3390/biomedicines10010161 · Cited by 15
“A recent cross-sectional study revealed that the NAFLD prevalence was 37.1% (95% CI, 34.0–40.4), whereas the MAFLD prevalence was slightly higher at 39.1% (95% CI, 36.3–42.1) in the general population of the United States of America [13].”
BackgroundInfluential
Metadata
- Authors
- Ciardullo, S., & Perseghin, G.
- Venue
- Liver International
- Publisher
- Wiley
- Published
- 2021-03-03
- Volume
- 41
- Issue
- 6
- Pages
- 1290-1293
- ISSN
- 0106-9543 (ISSN-L)
- 1478-3223
- 1478-3231
- OpenAlex
- W3132153535
- Cited by
- 191
- References
- 3
- FWCI
- 25.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population. https://app.cochat.ai/papers/10.1111/liv.14828
- The paper
- Ciardullo, S., & Perseghin, G. (2021). Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population. Liver International. https://doi.org/10.1111/liv.14828
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.